KC
CKPT

Kepos Capital’s Checkpoint Therapeutics CKPT Stock Holding History

Kepos Capital’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$311K – 622
2021
Q4 		$311K Hold
10,000
– – 0.03% 343
2021
Q3 		$330K Buy
+10,000
New +$296K 0.02% 406

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Kepos Capital's CKPT Position: Q1 2022 in Review

Kepos Capital sold out of Checkpoint Therapeutics (CKPT) in Q1 2022, closing a stake of 10,000 shares — an estimated $311K sold.

Kepos Capital first reported a position in CKPT in Q3 2021 and held it in 2 quarters. The position peaked at $330K in Q3 2021. 67 funds tracked by Wall St. Rank hold CKPT as of Q1 2022.

  • Kepos Capital reported no remaining Checkpoint Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Kepos Capital sold 10,000 Checkpoint Therapeutics shares in Q1 2022, an estimated $311K.
  • Kepos Capital first reported a position in Checkpoint Therapeutics in Q3 2021 and held it in 2 quarters.
  • Kepos Capital's Checkpoint Therapeutics position peaked at $330K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2022.

Based on Kepos Capital's 13F filing for Q1 2022, filed 13 May 2022.